BioAtla (BCAB)
(Delayed Data from NSDQ)
$1.73 USD
-0.03 (-1.70%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.81 +0.08 (4.62%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCAB 1.73 -0.03(-1.70%)
Will BCAB be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BCAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCAB
Does BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect?
Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?
BCAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates
BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
Other News for BCAB
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
BioAtla out-licenses BA3362 to Context Therapeutics
BioAlta out-licenses BA3362 to Context Therapeutics
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting